Understanding the molecular properties and metabolism of top prescribed drugs

Current Topics in Medicinal Chemistry

Volumn 13, Issue 11, 2013, Pages 1290-1307

  Zhong, Haizhen A ^a   Mashinson, Victoria ^a   Woolman, Theodor A ^a   Zha, Mengyi ^a  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Anticancer; Antidiabetes; Antihypertensives; Antipsychotics; Attrition; Combinational drugs; Molecular descriptors and metabolism; Molecular properties; Salt formation

Indexed keywords

4 AMINOPYRIDINE; ABACAVIR PLUS LAMIVUDINE; ABIRATERONE ACETATE; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALCAFTADINE; AMLODIPINE PLUS ATORVASTATIN; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS VALSARTAN; ATORVASTATIN; AXITINIB; AZILSARTAN MEDOXOMIL; BENZOYL PEROXIDE PLUS CLINDAMYCIN; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BICARBONATE PLUS OMEPRAZOLE; BOCEPREVIR; BOSUTINIB; BUDESONIDE PLUS FORMOTEROL; BUPRENORPHINE PLUS NALOXONE; CABAZITAXEL; CABOZANTINIB; CARFILZOMIB; CARGLUMIC ACID; CEFTAROLINE FOSAMIL; CHLORPHENIRAMINE POLISTIREX PLUS HYDROCODONE POLISTIREX; CIPRODEX OTIC; CLOBAZAM; CRIZOTINIB; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DABIGATRAN ETEXILATE; DEFERIPRONE; DIENOGEST PLUS ESTRADIOL VALERATE; DROSPIRENONE PLUS ETHINYLESTRADIOL; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELLA; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ERIBULIN; ESOMEPRAZOLE; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; EZETIMIBE PLUS SIMVASTATIN; FIDAXOMICIN; FINGOLIMOD; FLUTICASONE PROPIONATE PLUS SALMETEROL; GABAPENTIN ENACARBIL; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LAMIVUDINE PLUS ZIDOVUDINE; LINAGLIPTIN; LOPINAVIR PLUS RITONAVIR; LURASIDONE; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS SITAGLIPTIN; OLANZAPINE; PONATINIB; QUETIAPINE; REGORAFENIB; RETIGABINE; RILPIVIRINE; RIVAROXABAN; RUXOLITINIB; TELAPREVIR; TICAGRELOR; ULIPRISTAL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; VILAZODONE; VISMODEGIB;

ARTICLE; ATTENTION DEFICIT DISORDER; BACTERIAL SKIN DISEASE; BREAST METASTASIS; CEREBROVASCULAR ACCIDENT; COMMUNITY ACQUIRED PNEUMONIA; DRUG METABOLISM; EMBOLISM; HUMAN; HYPERAMMONEMIA; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; PROSTATE CANCER; SCHIZOPHRENIA; THYROID CANCER;

ADMINISTRATION, ORAL; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; DRUG DISCOVERY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INFUSIONS, PARENTERAL; MOLECULAR WEIGHT; PRESCRIPTION DRUGS; SOLUBILITY; STATIC ELECTRICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84881326128     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113139990034     Document Type: Article

References (30)

1. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 2004, 3, 711-715.
2. Lipinski, C. A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23, 3-25.
3. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. B.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
4. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov., 2007, 6, 881-890.
5. Lobell, M.; Hendrix, M.; Hinzen, B.; Keldenich, J.; Meier, H.; Schmeck, C.; Schohe-Loop, R.; Wunberg, T.; Hillisch, A. In silico ADMET traffic lights as a tool for the prioritization of HTS hits. ChemMedChem, 2006, 1, 1229-1236.
6. Vistoli, G.; Pedretti, A.; Testa, B. Assessing drug-likeness-what are we Messing? Drug Discov. Today, 2007, 13, 285-294.
7. Drugs. com, world wide web address: http://www.drugs.com/top 200.html (6/30/2011).
8. The DrugBank Database, http://www.drugbank.ca.
9. The SuperCyp Database, http://bioinformatics.charite.de/supercyp.
10. Drugs@FDA, FDA Approved Drug Products. World wide web: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
11. The Molecular Operating EnVironment (MOE); Chemical Computing Group Inc.: Montreal, Quebec, Canada, 2009.
12. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discov. 2002, 1, 727-730.
13. Walters, W. P.; Green, J.; Weiss, J. R.; Murcko, M. A. What do medicinal chemists actually make? A 50-year retrospective. J. Med. Chem. 2011, 54, 6405-6416.
14. Chen, H.; Engkvist, O.; Bloomberg, N.; Li, J. A comparative analysis of the molecular topologies for drugs, clinical candidates, natural products, human metabolites and general bioactive compounds. Med. Chem. Commun. 2012, 3, 312-321.
15. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 2008, 51, 817-834.
16. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A comparison of physicochemical property profiles of development and marketed oral drugs. J. Med. Chem. 2003, 46, 1250-1256.
17. Gleeson, M. P.; Hersey, A.; Montanari, D.; Overington, J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug. Discov. 2011, 10, 197-208.
18. Leeson, P. D.; St-Gallay, S. A.; Wenlock, M. C. Impact of ion class and time on oral drug molecular properties. Med. Chem. Commun. 2011, 2, 91-105.
19. Aakeröy, C. B.; Fasulo, M. E.; Desper, Cocrystal or salt: does it really matter? J. Mol. Pharm. 2007, 4, 317-322.
20. Berge, S. M.; Bighley, L. D.; Monkhouse, D. C. Pharmaceutical salts. J. Pharm. Sci. 1977, 66(1), 1-19.
21. Patsalos, P. N.; and Perucca, E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003, 2(6), 347-356.
22. Wienkers, L. C.; and Heath, T. G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug. Discov. 2005, 4, 825-833.
23. Sun, H.; Veith, H.; Xia, M.; Austin, C. P.; Huang, R. Predictive models for cytochromes P450 isozymes based on quantitative high throughput screening data. J. Chem. Inf. Model. 2011, 51, 2474-2481.
24. Wang, J. F.; Zhang, C. C.; Chou, K. C.; Wei, D. Q. Structure of cytochrome p450s and personalized drug. Curr. Med. Chem. 2009, 16, 232-244.
25. Arimoto, R. Computational models for predicting interactions with cytochrome p450 enzyme. Curr. Top. Med. Chem. 2006, 6, 1609-18.
26. Lewis, D. F.; Ito, Y. Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity. Xenobiotica 2009, 39, 625-35.
27. Lewis, F. V.; Modi, S.; Dickins, M. Quantitative structure-activity relationships (QSARs) within substrates of human cytochrome P450 involved in drug metabolism. Drug Metab. Drug Rev. 2001, 18, 221-242.
28. Snyder, R.; Sangar, R.; Wang, J.; Ekins, S. Three-dimensional quantitative structure-activity relationship for Cyp2D6 substrates. Quant. Struct.-Act. Relat. 2002, 21, 357-368.
29. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J. S.; Ring, B. J.; Wikel, J. H.; Wrighton, S. A. Three and four dimensionalquantitative structure-activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 1999, 9, 477-489.
30. Madden, J. C.; Cronin, T. D. Structure-based methods for the prediction of drug metabolism. Expert Opin. Drug Metab. Toxicol. 2006, 2, 545-557.